Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Atomoxetine hydrochloride

Nature Reviews Drug Discovery volume 3, pages 385–386 (2004)Cite this article

Abstract

Atomoxetine

In November 2002, atomoxetine hydrochloride (Strattera; Eli Lilly), a noradrenaline-reuptake inhibitor, was approved by the US FDA for the treatment of attention-deficit–hyperactivity disorder. As the first non-stimulant drug for this common but controversial condition, and also the first approved for the treatment of adults, what influence has it had on the market since its introduction?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Atomoxetine hydrochloride.
Figure 2: Market for drugs used to treat ADHD in US $ millions.

References

  1. Elia, J. et al. Treatment of attention-deficit–hyperactivity disorder. N. Engl. J. Med. 340, 780–788 (1999).

    Article  CAS  PubMed  Google Scholar 

  2. Zametkin, A. J. & Ernst, M. Problems in the management of attention-deficit–hyperactivity disorder. N. Engl. J. Med. 340, 40–46 (1999).

    Article  CAS  PubMed  Google Scholar 

  3. Wilens, T. E. et al. Attention deficit/hyperactivity disorder across the lifespan. Annu. Rev. Med. 53, 113–131 (2002).

    Article  CAS  PubMed  Google Scholar 

  4. Solanto, M. V. Dopamine dysfunction in AD/HD: integrating clinical and basic neuroscience research. Behav. Brain Res. 130, 65–71 (2002).

    Article  CAS  PubMed  Google Scholar 

  5. Biederman, J. & Spencer, T. Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol. Pyschiatry 46, 1234–1242 (1999).

    Article  CAS  Google Scholar 

  6. Wong, D. T. et al. A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. J. Pharmacol. Exp. Ther. 222, 61–65 (1982).

    CAS  PubMed  Google Scholar 

  7. Zerbe, R. L. et al. Clinical pharmacology of tomoxetine, a potential antidepressant. J. Pharmacol. Exp. Ther. 232, 139–143 (1985).

    CAS  PubMed  Google Scholar 

  8. Spencer, T. et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am. J. Psychiatry 155, 693–695 (1998).

    Article  CAS  PubMed  Google Scholar 

  9. FDA Drug Approvals List [online], (cited 6 Mar 2004). <http://www.fda.gov/cder/foi/label/2002/21411_strattera_lbl.pdf> (2002).

Download references

Author information

Authors and Affiliations

  1. Decision Resources Inc., 260 Charles Street, Waltham, 02453, Massachusetts, USA

    Melissa Garland

  2. Nature Reviews Drug Discovery,

    Peter Kirkpatrick

Authors
  1. Melissa Garland
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Melissa Garland.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Garland, M., Kirkpatrick, P. Atomoxetine hydrochloride. Nat Rev Drug Discov 3, 385–386 (2004). https://doi.org/10.1038/nrd1387

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1387

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing